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Abstract
Background: An inducible release of soluble junctional adhesion molecule-A (sJAM-A) under pro-inflammatory conditions
was described in cultured non-CNS endothelial cells (EC) and increased sJAM-A serum levels were found to indicate
inflammation in non-CNS vascular beds. Here we studied the regulation of JAM-A expression in cultured brain EC and
evaluated sJAM-A as a serum biomarker of blood-brain barrier (BBB) function.
Methodology/Principal Findings: As previously reported in non-CNS EC types, pro-inflammatory stimulation of primary or
immortalized (hCMEC/D3) human brain microvascular EC (HBMEC) induced a redistribution of cell-bound JAM-A on the cell
surface away from tight junctions, along with a dissociation from the cytoskeleton. This was paralleled by reduced
immunocytochemical staining of occludin and zonula occludens-1 as well as by increased paracellular permeability for
dextran 3000. Both a self-developed ELISA test and Western blot analysis detected a constitutive sJAM-A release by HBMEC
into culture supernatants, which importantly was unaffected by pro-inflammatory or hypoxia/reoxygenation challenge.
Accordingly, serum levels of sJAM-A were unaltered in 14 patients with clinically active multiple sclerosis compared to 45
stable patients and remained unchanged in 13 patients with acute ischemic non-small vessel stroke over time.
Conclusion: Soluble JAM-A was not suited as a biomarker of BBB breakdown in our hands. The unexpected non-inducibility
of sJAM-A release at the human BBB might contribute to a particular resistance of brain EC to inflammatory stimuli,
protecting the CNS compartment.
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Introduction
Junctional adhesion molecule-A (JAM-A) is a member of the
immunoglobulin superfamily. It is expressed in endothelial and
epithelial tight junctions, by mononuclear cells, neutrophils and
thrombocytes [1,2,3,4]. In endothelial and epithelial cells, JAM-
A contributes to the paracellular solute barrier by formation of
JAM-A homodimers within the cell membrane (in cis), binding
homodimers of neighbouring cells (in trans) [5,6,7,8,9]. Upon
inflammatory stimulation of endothelial cells (EC), JAM-A
redistributes from tight junctions to the apical cell surface where
it mediates immune cell adhesion in vitro under static and flow
conditions [10,11,12,13,14]. Chemokine-triggered leukocyte
transmigration across cultured EC is also mediated by endothe-
lial JAM-A, however without endothelial JAM-A redistribution
as a prerequisite [11]. T-cell and neutrophil adhesion and
transmigration governed by endothelial JAM-A were found to be
mediated by aLb2-integrin (Leukocyte Function Antigen-1,
LFA-1) on leukocytes [11], a result that could not be confirmed
by another group [15]. In line with the in vitro evidence
highlighting the importance of endothelial JAM-A for immune
cell extravasation, ex vivo perfusion of wire-injured carotid arteries
from JAM-A2/2 apoE2/2 mice with MM6 monocytic cells
demonstrated reduced MM6 extravasation in comparison to
arteries from JAM-A+/+ mice [16]. Neutrophil extravasation in
vivo in mice lacking endothelial JAM-A was found to be reduced
in a model of ischemia reperfusion injury of the liver [17] but not
of the heart [18]. Together these studies indicated a tissue-
specific role of endothelial JAM-A in the regulation of leukocyte
extravasation.
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A soluble form of JAM-A (sJAM-A) can be detected in the
peripheral blood [19]. Increased sJAM-A plasma or serum levels
compared to healthy controls were described in patients with
coronary artery disease, arterial hypertension, systemic sclerosis,
and renal insufficiency undergoing hemodialysis [19,20,21,22].
Two different groups recently identified human EC, namely
dermal microvascular EC (HDMEC) and umbilical vein EC
(HUVEC), as a cellular source of sJAM-A. Both EC types showed
a constitutive release of sJAM-A into culture supernatants which
was enhanced by pro-inflammatory stimulation [22,23]. These in
vitro data supported the blood level studies suggesting sJAM-A as a
biomarker of vascular inflammation. In HUVEC, sJAM-A was
found to be shedded from the cell surface by the disintegrin and
metalloproteinases (ADAM) 10 and 17 upon pro-inflammatory
stimulation [23]. On a functional level, recombinant sJAM-A
reduced adhesion of mononuclear cells to cultured HUVEC and
HDMEC [22,24]. Furthermore it reduced chemokine-triggered
endothelial transmigration of CD4+ CD45RO+ memory T cells
across HUVEC under static and flow conditions [24]. Finally,
recombinant sJAM-A inhibited neutrophil extravasation in vivo in
an air pouch model of vascular inflammation [23]. Based on these
results, it was suggested that sJAM-A might limit leukocyte
extravasation at sites of vascular inflammation. However, it was
also noted that all published experiments demonstrating a
reduction of leukocyte extravasation by recombinant sJAM-A
used concentrations too high to allow final conclusions about the
pathophysiological function of sJAM-A in vivo [23]. To date, the in
vivo function of sJAM-A has not finally been addressed.
To protect CNS homeostasis, EC forming the blood-brain
barrier (BBB) are highly specialized and differ in many molecular
aspects from other EC types such as HUVEC [25,26]. A potential
role of JAM-A at the BBB under inflammatory conditions was
indicated by a study reporting reduced brain endothelial JAM-A
immune staining in the rat cortical cold injury model [27].
Reduced endothelial JAM-A immune staining was also observed
in active brain lesions of patients with multiple sclerosis (MS)
[28,29]. No major difference of brain EC JAM-A expression levels
was noted between mice with cytokine-induced meningitis and
sham-treated animals [30]. The expression of sJAM-A at the BBB
has not been investigated so far.
Here we studied the regulation of JAM-A expression in cultured
human brain microvascular EC (HBMEC) and evaluated sJAM-A
as a serum marker of BBB breakdown. While inflammatory
stimulation of cultured HBMEC induced a subcellular redistribu-
tion of cell-bound JAM-A as previously described in other EC
types, a detected constitutive release of sJAM-A was unexpectedly
neither enhanced by pro-inflammatory nor by hypoxia/reoxy-
genation challenge. Accordingly, sJAM-A serum levels did not
indicate a BBB breakdown in vivo. These results define a novel
feature of human brain EC, distinguishing them from other EC
types and possibly contributing to their particular anergy in the
protection of CNS homeostasis.
Materials and Methods
Cell Culture
Cryopreserved single donor primary HBMEC isolated from
normal human brain were purchased from Cell Systems (Kirk-
land, WA) at passage 2. Each preparation was extensively
characterized as previously described [31]. Cells were plated on
2% gelatin-coated culture dishes or flasks of various sizes
depending on the experiment (all from Nunc, Roskilde, Denmark)
and cultured at 37uC, 5% CO2 in M199 medium containing 10%
fetal calf serum, 20 mg/mL endothelial cell growth supplement
(20 mg/mL; Sigma-Aldrich, Deisenhofen, Germany), 100 mg/mL
heparin, 250 mg/mL amphotericin B, 50 mg/mL gentamycin,
50 U/mL penicillin and 50 mg/mL streptomycin. HBMEC were
used at passage 4 and 5 for experiments. A well characterized
immortalized HBMEC line, hCMEC/D3, was cultured as
previously described [32]. For hypoxia experiments, EC were
cultured in a C60 incubator from Labotect (Go¨ttingen, Germany).
Immunocytochemistry
For immunocytochemistry, cells were either fixed with 3.7%
paraformaldehyde (PFA) for 10 min and permeabilized with 0.1%
Triton X-100 for 6 min at room temperature (JAM-A, ZO-1) or
fixed with a fresh 1:1 mixture of methanol and acetone for 10 min
at 220uC (occludin), and then washed with washing buffer
containing 0.2% gelatin in Dulbecco’s phosphate-buffered saline.
Subsequently, primary mouse monoclonal antibodies against
JAM-A (clone M.Ab.F11, AbD Serotec, Du¨sseldorf, Germany),
zonula occludens-1 (ZO-1, clone ZO-1-1A12, Zymed, San
Francisco, CA) or occludin (clone OC-3F10, Zymed) were
incubated at 4uC overnight. Subsequently, a Cy3-coupled anti-
mouse secondary antibody was incubated for 1 h at room
temperature. F-actin staining was performed with Alexa Fluor
488 phalloidin according to the instructions of the manufacturer
(Invitrogen, Karlsruhe, Germany). Nuclei were counterstained
with DAPI. Finally, an antifading agent (Dabco, Merck, Germany)
was added. Negative controls were performed by omitting the
primary antibodies as well as by staining with isotype-matched
control antibodies. The stainings were analyzed by an Olympus
IX-70 inverted system microscope with IX-FLA observation
attachment for fluorescence imaging.
Dextran Permeability Assay
To assess the paracellular permeability of HBMEC for dextran
3000 a transwell system was used. 16105/well HBMEC in 200 mL
medium were seeded onto polycarbonate membrane inserts (pore
size 0.4 mm, surface area 0.33 cm2) purchased from Corning Inc.
(Cat. no. 3413, Corning, NY). After reaching confluence (as
confirmed by DAPI staining of filters grown in parallel), cells were
left untreated or stimulated as indicated for 24 hours. Then the
cell culture medium was replaced by sterile-filtered, prewarmed
(37uC) 10 mM HEPES buffer, pH 7.2, containing 0.1% bovine
serum albumin and 4.5% (w/v) glucose. After equilibration of the
cells for 5 min at 37uC, 5% CO2 FITC-dextran 3000 (Sigma-
Aldrich) was added to the upper chambers in a volume of 4 mL
and to a final concentration of 1 mg/mL, and incubated at 37uC,
5% CO2 for 90 min. Thereafter relative fluorescence in the lower
chambers was determined using a Fluoroskan AscentH (Thermo
Electron Corporation, Dreieich, Germany) microplate fluorometer
at an excitation wavelength of 485 nm and an emission
wavelength of 538 nm. All experiments were performed in
octuplicates. FITC-dextran clearance through coated and uncoat-
ed filters with no cells attached served as additional control
conditions.
Flow Cytometry
Resting and stimulated EC were harvested and dissociated with
AccutaseTM (Sigma-Aldrich), a mixture of proteolytic and
collagenolytic enzymes from an invertebrate species. Single cell
suspensions were then stained according to a standard protocol as
previously described [31] using M.Ab.F11, rabbit anti-human
JAM-A (Cat. no. 36–1700, Zymed), or fluorescein-coupled
monoclonal mouse anti-human intercellular adhesion molecule-1
(ICAM-1, clone BBIG-I1, R&D Systems, Karlsruhe, Germany)
and appropriate isotype controls as primary antibodies, and
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analyzed using a Beckton-Dickinson (Mountain View, CA)
fluorescence-activated cell sorter.
Western Blotting
For generation of whole cell protein extracts, cells grown to
subconfluency in 25 cm2 flasks were stimulated as indicated,
washed with icecold PBS and scraped into radioimmunoprecip-
itation assay (RIPA) buffer composed of 50 mmol/L Tris-HCl,
pH 7.4; 150 mmol/L NaCl; 1% Nonidet P40; 0.25% sodium
deoxycholate and 16 Roche COMPLETEH protease inhibitor
mix (Roche Diagnostics GmbH, Mannheim, Germany). Samples
were shaken vigorously for 30 minutes, and then centrifuged at
20,000 g for 20 minutes at 4uC. Supernatants were subjected to
Western blot analysis.
For analysis of sJAM-A levels in cell culture supernatants
1.3 mL cell culture supernatant were transferred to an 1.5 mL
Eppendorf tube. After addition of 35 mL sodium deoxycholate
10% and gentle mixing samples were incubated at room
temperature for 10 minutes. Thereafter 150 mL trichchloroacetic
acid 77% were added, samples were vortexed and incubated on
ice for 30 minutes, and then centrifuged at 20,000 g for 20
minutes at 4uC. Then all supernatant was carefully removed,
300 mL ice-cold acetone were added and samples were centrifuged
at 20,000 g for 5 minutes at 4uC. Thereafter the supernatant was
carefully removed and the pellet was dried. After resuspension in
equal amounts of loading buffer and heating at 65uC for 3 minutes
samples were subjected to SDS-PAGE.
M.Ab.F11, rabbit anti-human JAM-A (Zymed) or goat anti-
human JAM-A (Cat. no. AF-1103, R&D) were used as primary
antibodies for JAM-A detection as indicated. Appropriate
peroxidase-coupled secondary antibodies were employed with a
standard enhanced chemoluminescence system (Amersham,
Arlington Heights, IL, USA). After peroxidase inactivation, the
same membranes were reprobed with a rabbit polyclonal or a
mouse monoclonal antibody against b-actin (both from Sigma-
Aldrich) as a loading control.
Enzymatic N-Deglycosylation
N-deglycosylation was performed using the GlycoProfileTM II
Enzymatic In-Solution N-Deglycosylation kit by Sigma-Aldrich
according to the instructions of the manufacturer. In brief, 50 mg
of a whole cell protein extract generated by the RIPA lysis buffer
described in the previous section were denaturated by addition of
n-octyl-D-glucopyranoside and 2-mercaptoethanol, and incuba-
tion at 100uC for 10 min. Then the samples were incubated with
the indicated amounts of PNGase F in incubation buffer for 2 h.
N-glycosylated recombinant RNase B was digested in parallel as a
positive control. The reaction was stopped by heating at 100uC for
10 min. Finally, the samples were analyzed on Western blots.
Enzyme-Linked Immunosorbent Assay
To detect sJAM-A we developed a sandwich ELISA employing
NUNC Maxi Sorp 96-well plates and appropriate reagents from
R&D Systems: goat anti-human JAM-A (Cat. no. AF1103) at 4uC
overnight as capture antibody, biotinylated goat anti-human JAM-
A (Cat. no. BAF 1103) at 37uC for 30 min as detection antibody,
recombinant human JAM-1/Fc chimera (Cat. no. 1103-JM) for
the standard curve which was run on every ELISA plate and the
substrate reagent pack DY999. All samples were measured in
duplicates. Furthermore all serum samples were measured
undiluted, at 1:20 and at 1:400 dilution in parallel. The minimum
detectable concentration defined as standard curve duplicate
significantly exceeding the background signal was 1.526 ng/mL in
all assays used for sample measurement. While JAM-A could be
detected in all serum samples, JAM-A in cell culture supernatants
could consistently be detected only after protein concentration by
filter centrifugation, using Amicon Ultra-15 Ultracel-10k filter
devices (Millipore Corporation, Tullagreen, Ireland). This proce-
dure revealed a ,10-fold JAM-A concentration as determined by
filter centrifugation of dilutions of recombinant JAM-A in
complete medium.
Patients
The study was performed in accordance to the Declaration of
Helsinki. It was approved by the local ethics committees. Written
informed consent was given by all patients.
All MS patients were treated at the University of Wu¨rzburg,
Department of Neurology, and had relapsing-remitting MS
according to the McDonald criteria [33]. Clinical details are
provided in online supplementary Table S1. None of the MS
patients had received treatment with corticosteroids, interferon-b,
glatiramer acetate, azathioprine, natalizumab or mitoxantrone
during the 3 months preceding blood withdrawal for study
participation, most often due to patient denial of secondary
prophylactic pharmacotherapy. High-dose corticosteroid treat-
ment in the relapse group was initiated after blood withdrawal for
this study. Group assessment of MS patients (active vs. stable) was
solely based on clinical parameters as gadolinium-enhanced MRI
scans around the time point of blood withdrawal were available
only for a minority of clinically active patients (n = 3) because high-
dose steroid pulse therapy, which effectively suppresses gadolinium
enhancement, was started at the day of admission in most patients
with an acute relapse while MRI scans were not immediately
available in most of these patients due to logistic reasons. Most
stable patients were seen in an outpatient setting and had not
received very recent MRI scans.
All patients with non-small vessel ischemic stroke were treated at
the University of Frankfurt, Department of Neurology. Serum
samples were collected within the framework of a prospective
study on stroke biomarkers [34]. We selected all patients with
complete ischemic stroke not undergoing hemorrhagic stroke
transformation in the course of their disease, for whom serum
samples both collected within the first 3 h after clinical onset of
symptoms and 24 h thereafter were available (n = 13). See online
supplementary Table S2 for clinical details.
Statistics
Levels of sJAM in HBMEC culture supernatants were analyzed
by the Kruskal-Wallis test. To compare baseline characteristics of
study participants we used the Mann-Whitney U test or the chi-
square test. To analyze permeability assays or to compare JAM-A
serum levels between MS patients with stable disease and other
MS patients during an acute relapse the Mann-Whitney U test
was employed. For comparison of serum levels in stroke patients
over time we used the Wilcoxon matched pairs test. A p value
,0.05 was considered statistically significant. All data were
analyzed with GraphPad PRISM 4 software (GraphPad Software,
La Jolla, CA).
Results
JAM-A in Cultured HBMEC Is Redistributed at the
Subcellular Level upon Inflammatory Stimulation
To investigate whether JAM-A is expressed in cultured primary
HBMEC and to study its expression and subcellular localization
under inflammatory conditions we first performed immunocyto-
chemical staining of primary single donor HBMEC preparations
employing M.Ab.F11 for JAM-A staining, the monoclonal
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antibody by which JAM-A was originally identified [1]. As
observed for the transmembranous tight-junction protein occludin
and the intracellular adapter protein ZO-1, JAM-A staining was
linear and localized to tight junctions under resting conditions.
The signal was reduced and more punctuate upon stimulation for
24 h with tumour necrosis factor-a (TNF-a) and interferon-c
(IFN-c). In parallel we observed a reorganization of the actin
cytoskeleton with formation of stress fibers (Figure 1A). Altered
tight junction morphology under inflammatory conditions corre-
sponded to an increased paracellular permeability for dextran
3000, as determined in transwell assays (Figure 1B). Flow
cytometric analysis of AccutaseTM-dissociated single cell suspen-
sions with two different antibodies against JAM-A demonstrated
that overall JAM-A cell surface expression levels did not change
upon inflammatory stimulation with TNF-a and IFN-c while
intercellular adhesion molecule-1 (ICAM-1), serving as a positive
control, was upregulated on the cell surface (Figure 2). Western
blot experiments with M.Ab.F11 as primary antibody showed that
TNF-a and IFN-c enhanced the Nonidet-P40 soluble fraction of
JAM-A in a slightly additive manner, indicating JAM-A
dissociation from the cytoskeleton (Figure 3A). In contrast to
recent results in HUVEC where JAM-A was detected as a single
band at 43 kDa, or 38 kDa after N-deglycosylation [23], JAM-A
in HBMEC was detected as a single band at 35–37 kDa
depending on the cell preparation. This corresponded to the
JAM-A size of 37 kDa reported in hCMEC/D3 by Huang and
colleagues [35], which was confirmed by our experiments using
hCMEC/D3 (data not shown). After N-deglycosylation, JAM-A
appeared as a uniform band at ,35 kDa, indicating that the
molecular weight variability of JAM-A in HBMEC was due to
differential N-glycosylation (Figure 3B). In summary, our results
indicate a redistribution of JAM-A away from tight junctions and
dissociation from the actin cytoskeleton under pro-inflammatory
conditions while overall cell surface expression levels do not
change. Similar results were obtained when using the immortal-
ized human brain EC line hCMEC/D3 (data not shown).
Figure 1. Immunocytochemical JAM-A tight junction staining in primary HBMEC is reduced under barrier-disturbing pro-
inflammatory conditions. Cells were either left unstimulated or treated with TNF-a 10 ng/mL and IFN-c 100 U/mL for 24 h. A
Immunocytochemical staining was performed with primary antibodies against JAM-A (M.Ab.F11), occludin and ZO-1. F-Actin was stained with
Alexa Fluor 488 phalloidin. Representative for 5 independent experiments with different HBMEC preparations. B Analysis of paracellular barrier
function by dextran 3000 transwell permeability assays. Mean and SD of 4 independent experiments in octuplicates with different HBMEC
preparations. The two-tailed Mann-Whitney U test was used for statistical analysis. Bar = 25 mm.
doi:10.1371/journal.pone.0013568.g001
Figure 2. In contrast to ICAM-1, JAM-A overall surface expression levels on HBMEC do not change upon pro-inflammatory
stimulation. Flow cytometric analysis of AccutaseTM-dissociated single cell suspensions of primary HBMEC after stimulation as in Figure 1. JAM-A
was stained with M.Ab.F11 and a rabbit polyclonal antibody from Zymed. Staining against ICAM-1 served as a positive control. In parallel,
unstimulated and stimulated HBMEC were stained with matched isotype control antibodies. Filled histograms represent isotype stainings, open
histograms JAM-A and ICAM-1 stainings. Representative for 5 independent experiments with different HBMEC preparations.
doi:10.1371/journal.pone.0013568.g002
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Cultured HBMEC Constitutively Release sJAM-A, which Is
not Altered under Inflammatory and Hypoxia/
Reoxygenation Conditions
Having observed a similar inflammatory-induced alteration of
cell-bound JAM-A expression as previously described in non-CNS
EC types, we next investigated whether HBMEC show a basal or
inducible release of sJAM-A as previously described in HUVEC
and HDMEC [22,23]. To measure sJAM-A, we developed a
sandwich ELISA. When used for Western blot experiments with
whole cell protein extracts, the goat anti-JAM-A antibody which
was employed as capture antibody for this ELISA detected the
same 35–37 kDa protein studied in Figure 1, 2, 3 (Figure 4A).
Figure 4B shows a typical standard curve of the ELISA. We
detected a basal release of sJAM into primary HBMEC (Figure 4C)
and hCMEC/D3 (Figure 4D) culture supernatants which was
neither altered by stimulation with TNF-a and IFN-c for 48 h nor
by exposure to 1% O2 for 24 h followed by a reoxygenation period
of 24 h. Soluble JAM-A was not detected in complete medium
without previous cell contact; concentrations increased over time
of cell culture; and cell densities were not significantly influenced
by stimulation conditions (data not shown). To confirm the key
result of unaltered sJAM-A release during inflammatory or
hypoxia/reoxygenation challenge by an alternative method, we
additionally investigated sJAM-A levels in TCA-precipitated
protein extracts from culture supernatants of primary HBMEC
by Western blotting. A preceding comparative analysis of whole
cell protein extracts and TCA-precipitated culture supernatants
revealed, that sJAM-A had a smaller molecular weight than JAM-
A in whole cell protein extracts. In supernatants, we detected two
bands of ,33 and ,25 kDa (Figure 4E). Importantly, neither
stimulation with TNF-a and IFN-c for 48 h nor exposure to 1%
O2 for 24 h followed by a reoxygenation period of 24 h altered the
release of sJAM-A as detected by Western blotting which
confirmed the results obtained by ELISA (Figure 4F). Serum
starvation (2% FCS) prior to stimulation did not result in an
inflammatory- or hypoxia/reoxygenation-inducible sJAM-A re-
lease from HBMEC either, as measured by ELISA (data not
shown).
Serum Levels of sJAM-A in Patients with Multiple
Sclerosis and Ischemic Stroke Do not Reflect Disturbance
of the Blood-Brain Barrier
To investigate whether the release of sJAM-A from HBMEC in
vivo is increased in disorders with disturbance of the BBB we first
compared JAM-A serum levels in 45 clinically stable patients with
relapsing-remitting MS not receiving immune therapy to serum
levels in 14 active untreated MS patients not yet receiving steroid
therapy during an acute relapse. Group assessments of MS
patients were solely based on clinical parameters. No significant
difference of sJAM-A serum levels was detected between
both groups (Figure 5A). No specific clinical characteristics could
be identified in 5 MS patients with high serum levels above
100 ng/mL. Next we investigated sJAM-A serum levels in 13
patients with acute, non-small vessel, complete ischemic stroke
over time. A first set of serum samples was obtained within the first
3 h after clinical onset of symptoms when no significant alteration
of tight junction molecule expression at the BBB is to be expected
[36]. Another set of serum samples was obtained 24 h after onset
of symptoms in a phase where commonly severe BBB disruption is
observed in patients with complete ischemic stroke which was
demonstrated in all stroke patients by repeated cranial imaging
[37]. No significant alteration of sJAM-A serum levels over time in
this group of patients was seen (Figure 5B). Our in vitro
observations support the notion that soluble JAM-A is not
inducibly released by HBMEC during inflammatory- or hypox-
ia/reoxygenation-induced BBB breakdown in vivo.
Discussion
The major finding of this study is that in contrast to previously
reported EC types, cultured human brain EC do not show an
inducible release of sJAM-A under pro-inflammatory conditions,
while the expression of cell-bound JAM-A upon pro-inflammatory
stimulation is altered as previously described in other EC types.
Accordingly, sJAM-A was not suited as a serum biomarker of
human BBB breakdown in our hands.
The observed inducible loss of immunocytochemical JAM-A
tight junction staining under pro-inflammatory conditions along
with decreased staining of occludin and ZO-1 and a reorganiza-
tion of the actin cytoskeleton, as well as an increase of the Nonidet-
P40 soluble JAM-A fraction corresponds to previous results
obtained with HUVEC and the murine heart microvascular EC
line H5V, although the molecular weight of JAM-A is slightly
higher in HUVEC compared to HBMEC [10,12,23]. This
difference was found to be partially attributable to differential
N-glycosylation of JAM-A in both cell types. Expression levels of
cell-bound JAM-A on HBMEC as determined by flow cytometry
and sJAM-A concentrations in cell culture supernatants from
HBMEC under different culture conditions were found to be
much lower than previously reported in HUVEC [19]. Differential
JAM-A expression levels might therefore reflect cell-type specific
differences. Our observation of subcellular JAM-A redistribution
on HBMEC upon inflammatory stimulation with an overall
reduction of immunocytochemical JAM-A staining adds in vitro
Figure 3. Pro-inflammatory stimulation of HBMEC induces
JAM-A dissociation from the actin cytoskeleton. A Primary
HBMEC were either left unstimulated or treated with TNF-a 10 ng/mL or
IFN-c 100 IU/mL alone or in combination. Cell protein extracts were
generated with a Nonidet-P40 based cell lysis buffer and subjected to
Western blot analysis. JAM-A was stained with M.Ab.F11. Staining of the
same, peroxidase-inactivated membranes with a rabbit antibody
against b-actin served as a loading control. B N-deglycosylation of
JAM-A with increasing concentrations of PNGase F for 2 h. A rabbit
polyclonal antibody against JAM-A (Zymed) was used for the detection
of JAM-A. The asterisk represents N-glycosylated, the open circle N-
declycosylated JAM-A. Representative experiments out of at least 5
independent experiments with different EC preparations for each
subpanel of the figure are shown.
doi:10.1371/journal.pone.0013568.g003
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Figure 4. HBMEC constitutively release sJAM-A, which is not altered under inflammatory or hypoxia/reoxygenation conditions.
A Representative Western blot of a HBMEC whole cell protein extract, employing the goat anti-JAM-A antibody which was used as capture antibody
for a self-developed sandwich ELISA (compare Figure 3). B Typical standard curve of the self-developed ELISA for JAM-A detection in culture
supernatants and serum. C and D Concentrations of sJAM-A in culture supernatants of primary HBMEC (C) or hMCEC/D3 (D) which were either left
unstimulated for 48 h, stimulated with TNF-a 10 ng/mL and IFN-c 100 U/mL for 48 h or subjected to 1% O2 for 24 h followed by a reoxygenation
period of 24 h. Please note: cell culture supernatants were concentrated by filter centrifugation before ELISA measurement, resulting in ,10-fold
increased JAM-A concentration. Mean and SD of 3 independent experiments. The Kruskal-Wallis test was used for statistical analysis. n.s., not
significant. E Comparative Western blot analysis of a whole cell protein extract and a TCA-precipitated protein extract from cell culture supernatant,
using a rb polyclonal antibody (Zymed) for JAM-A detection. Representative of 3 independent experiments with different HBMEC preparations. The
Soluble JAM-A at the Human BBB
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evidence to in situ studies describing reduced immunohistochem-
ical JAM-A staining at the BBB under inflammatory conditions
[27,29].
As recently reported for HUVEC and HDMEC [22,23], we
detected a constitutive release of sJAM-A from HBMEC into cell
culture supernatants. However, in contrast to these cell types, the
release of sJAM-A from HBMEC was not increased by pro-
inflammatory stimulation with TNF-a and IFN-c. This relative
anergy of HBMEC in comparison to other EC types might reflect
a particular resistance of HBMEC to inflammatory stimuli,
protecting the CNS compartment. The release of sJAM from
cultured HBMEC was not enhanced under hypoxia/reoxygena-
tion conditions either, a condition that has not been studied in
other EC types in the context of sJAM-A release so far. The
parallel use of primary HBMEC and a well established
immortalized HBMEC line, hCMEC/D3, for all in vitro
experiments revealed comparable results, arguing for the robust-
ness of our in vitro results.
Our in vitro results of a constitutive, but not an inducible, sJAM-
A release by brain EC corresponded to our in vivo finding that
sJAM-A serum levels in MS patients during an acute relapse and
in patients with acute ischemic stroke remained stable. These
results are in contrast to studies describing elevated sJAM-A serum
levels in patients with inflammation in vascular compartments
outside the brain [20,21,22]. Our in vitro results suggest that the
stability of sJAM-A serum levels in patients with clinically active
MS or ischemic stroke was rather due to a non-release at the BBB
than to a masking effect by sJAM-A from other cellular sources.
The detectable BBB disturbance in patients with a MS relapse
might be subtle and focal, and our group assessment of MS
patients was limited by the non-availability of MRI data, but
ischemic stroke in a major territory, which was proven in all stroke
patients by repeated cranial imaging, is always associated with a
severe breakdown of the BBB 24 h after onset. Therefore, a
release of sJAM-A, if present, should have been detectable in
patients with stroke.
Based on our results it appears that sJAM-A is not suited as a
serum biomarker for BBB breakdown in humans, which is in
contrast to vascular cell adhesion molecule-1 (VCAM-1). Soluble
VCAM-1 serum levels were reported to positively correlate in MS
patients with clinical disease activity and an inflammatory BBB
breakdown as indicated by Gadolinium-enhancing MRI lesions
[38,39]. Furthermore, enhanced serum levels of soluble VCAM-1
were reported in patients with ischemic stroke [40,41]. Soluble
VCAM-1 is released from HBMEC upon pro-inflammatory
stimulation through a marimastat-inhibitable process [42], prob-
ably reflecting ADAM17 activation as demonstrated in murine EC
[43]. JAM-A was found to be shedded from HUVEC by
ADAM10 and 17 [23]. The cited studies in brain EC indicate
that differences of inducible sJAM release under pro-inflammatory
conditions between HBMEC and HUVEC are rather not due to
differential ADAM17 activation in both cell types. The reason for
a differential release of sJAM-A upon inflammatory stimulation of
different EC types currently remains unknown.
Given that brain EC exhibit particularly strong barrier
properties protecting the CNS, our results of a missing inducible
sJAM-A release under pro-inflammatory conditions might some-
how challenge the view that sJAM-A blocks leukocyte extravasa-
tion in vivo under pathophysiological conditions, as suggested by
studies using recombinant JAM-A in vitro and in vivo [22,23,24]. Of
note and in contrast to sJAM-A, the expression of cell-bound JAM-
A in brain EC upon inflammatory stimulation in vitro is regulated
as previously described in other EC types. It is well established that
altered expression of cell-bound JAM-A under inflammatory
conditions may facilitate leukocyte extravasation [10,11,12,16,17].
If the inducible release of sJAM-A under pro-inflammatory
conditions really serves to limit leukocyte extravasation in vivo it
is surprising that an EC type known for its strong barrier
asterisk represents full-length JAM-A, open circles represent soluble JAM-A. F Comparative Western blot analysis of JAM-A in TCA-precipitated cell
culture supernatants, using the same primary antibody as in E, after stimulation as in C and D. Representative of 3 independent experiments with
different HBMEC preparations. Abbreviations: WCE, whole cell protein extract; SN, supernatant.
doi:10.1371/journal.pone.0013568.g004
Figure 5. Soluble JAM-A serum levels do not indicate BBB
disturbance in multiple sclerosis and ischemic stroke. A Levels
of sJAM-A in serum samples from 45 patients with stable relapsing-
remitting MS not receiving secondary prophylactic therapy were
measured in duplicates by ELISA and compared to those in 14
untreated MS patients during an acute relapse. B Levels of sJAM-A were
measured in serum samples from 13 patients with non-small vessel
complete ischemic stroke where a first sample was obtained within the
first 3 h of symptom onset and a second sample 24 h after clinical
onset. Serum samples were not concentrated before ELISA measure-
ment. Dots represent single values, lines median values. Serum levels in
stable and inflammatory-active MS patients were statistically compared
by the Mann-Whitney U test, serum levels in stroke patients over time
by the Wilcoxon matched pairs test. n.s., not significant.
doi:10.1371/journal.pone.0013568.g005
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properties does not exhibit this inflammation-limiting feature while
at least in vitro JAM-A functions allowing leukocyte extravasation,
i.e. redistribution to the cell surface under inflammatory
conditions, seem to function like in other vascular beds.
In summary, we demonstrated that the regulation of JAM-A cell
surface expression and the release of sJAM-A by both primary and
immortalized human brain endothelium share some features with
EC types from other parts of the body but also show unique
properties of brain EC, not described in other EC types so far. The
non-inducibility of sJAM-A release by brain EC might reflect their
special role in the protection of the CNS compartment.
Supporting Information
Table S1 Clinical characteristics of multiple sclerosis patients.
The table provides a comparison between stable and active
patients concerning age, gender, disease duration and Expanded
Disability Status Scale (EDSS), reflecting the degree of disability.
Found at: doi:10.1371/journal.pone.0013568.s001 (0.03 MB
DOC)
Table S2 Clinical characteristics of ischemic stroke patients. The
table lists age, gender, NIH Stroke Scale (NIHSS) at admission,
infarct size, type of infarct according to the TOAST criteria, time
from clinical onset to first blood withdrawal and whether or not
systemic thrombolysis was performed for all patients taking part in
this study.
Found at: doi:10.1371/journal.pone.0013568.s002 (0.05 MB
DOC)
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